About Sanofi-Aventis

Sanofi-Aventis, (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is the world's number third largest company in the pharmaceutical industry after Pfizer and GlaxoSmithKline and number one in Europe. The pharma giant engages in the research, development, manufacture and marketing of pharmaceutical products for sale primarily in the presciption drugs market.

Sanofi-Aventis covers 7 therapeutic areas which includes: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The company has about 100,000 employees worldwide which includes 33,000 sales persons.

The pharmaceutical company has its presence in more than 100 countries throughout the 5 continents. The company is committed to find new compounds that bring hope and are essential to medical progress. It's equally committed to providing millions of patients with new, innovative and efficacious drugs to combat disease, to participate actively in making medicines accessible to the greatest number of people possible, and to ensure that the development of the Group is integrated into a strategy of strong, sustainable and profitable growth.

The company has numerous resources that constitute the basis of its identity and creativity in the global pharmaceutical industry. Its research organization ranks among the best in the world and with 11,000 scientific personnel by its side, the company is a leader in major therapeutic areas such as cardiovascular disease, thrombosis, cancer, diabetes, central nervous system disorders, internal medicine, and vaccines.

Acomplia, a new age weight loss drug, is the latest drug developed by Sanofi-Aventis for providing relief to millions of obese people as well as smokers.